Section Arrow
IONS.NASDAQ
- Ionis Pharmaceuticals
Quotes are at least 15-min delayed:2025/01/11 11:16 EST
Last
 33.46
-0.64 (-1.88%)
Day High 
33.77 
Prev. Close
34.1 
1-M High
39.08 
Volume 
1.17M 
Bid
33.44
Ask
33.46
Day Low
33.15 
Open
33.66 
1-M Low
33.92 
Market Cap 
5.38B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 35.13 
20-SMA 36.03 
50-SMA 36.65 
52-W High 53.165 
52-W Low 33.33 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.44/-2.69
Enterprise Value
6.78B
Balance Sheet
Book Value Per Share
4.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
787.65M
Operating Revenue Per Share
3.90
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 11:16 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.